Immunotherapy
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promising evidence of immune activation consistent with levels of activity observed in patients from the…
Read More
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial sites activated to date and on plan for site expansion to accelerate patient recruitment Excerpt from the Press Release: LAWRENCEVILLE, N.J.,…
Read More
The researchers identified a potential therapeutic vulnerability in pediatric high-grade gliomas Excerpt from the Press Release: PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ — A new study, led by researchers at Children’s Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing in pediatric high-grade glioma tumors but not in normal brain tissues. Preclinical…
Read More
Phase 1 clinical trial of ADI-001 in autoimmune diseases actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc Preliminary clinical data from Phase 1 trial of ADI-001 in autoimmune diseases expected in 2H/2025 Excerpt from the Press Release: REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage…
Read More
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile Excerpt from…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., July 2, 2025 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy, today presented new clinical data from the ongoing STARt-001 Phase 1/2 trial of Invikafusp alfa during an oral session at the European Society of Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025.…
Read More
Study will evaluate OX-4224 as a second-line monotherapy in patients with PD-L1–positive non-small cell lung cancer, expanding potential access to checkpoint inhibitors in low-resource settings Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–OmRx Oncology, or “OmRx,” a clinical-stage biopharmaceutical venture dedicated to expanding access to cancer immunotherapy worldwide, today announced the initiation of a Phase…
Read More
Research shows potential for brain-specific replacement over Hematopoietic Stem Cell Transplantation, which impacts the entire immune system Excerpt from the Press Release: PHILADELPHIA, April 30, 2025 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania announced the first ever direct approach to the depletion and…
Read More
I Peace, in Cooperation with SBI Holdings, Unveils Next-Gen Cell Mass-Manufacturing System “EGG” at SBI Holdings Inc. booth in the Osaka Healthcare Pavilion “Nest for Reborn” at the 2025 World Expo, Osaka Excerpt from the Press Release: PALO ALTO, Calif. , April 24, 2025 /PRNewswire/ — I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived…
Read More